NewAmsterdam Pharma Company N.V. (NAMS)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
NewAmsterdam Pharma Company N.V. has not issued a press release in this window.
SEC filings
All filings →NewAmsterdam Pharma Company N.V. has not filed an SEC document in this window.
Insider trades
All insider trades →NewAmsterdam Pharma Company N.V. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for NewAmsterdam Pharma Company N.V. in this window.
People at NewAmsterdam Pharma Company N.V.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for NewAmsterdam Pharma Company N.V..